

26. The method of any one of claims 1-24, further comprising informing a patient for whom the presence of a mutation to AKT is determined that an AKT inhibitor should not be administered.

~~27. Use of GDC-0068 or a salt thereof in the manufacture of a medicament for treating a cancer cell having a mutation to AKT, wherein the presence of a mutation to AKT correlates with sensitivity of the cell to the AKT inhibitor, wherein the mutation corresponds to, or aligns with, L52, K189 or D323.~~